CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

brolucizumab

Last Updated: July 3, 2020
Result type: Reports
Project Number: SR0632-000
Product Line: Reimbursement Review

Generic Name: brolucizumab

Brand Name: Beovu

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Macular degeneration, age-related

Manufacturer Requested Reimbursement Criteria1: For the treatment of neovascular (wet) age-related macular degeneration.

Submission Type: Initial

Project Status: Complete

Companion Diagnostics: No

Date Recommendation Issued: May 21, 2020

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted August 28, 2019
Patient group input closed October 18, 2019
Clarification:

- Patient input submission received from Canadian Council of the Blind, CNIB Foundation, Fighting Blindness Canada, Vision Loss Rehabilitation Canada (Joint Submission)

Patient input summary sent for review to patient input groups December 04, 2019
Patient group comments on input summary closed December 11, 2019
Clarification:

- No patient input summary feedback received

Submission received September 26, 2019
Submission accepted November 28, 2019
Clarification:

- Submission was not accepted for review on 10-Oct-2019

- Revised category 1 requirements received on 25-Nov-2019

Review initiated November 29, 2019
Draft CADTH review report(s) sent to sponsor February 20, 2020
Comments from sponsor on draft CADTH review report(s) received March 02, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsor April 02, 2020
Canadian Drug Expert Committee (CDEC) meeting April 15, 2020
CDEC recommendation sent to sponsor and drug plans April 29, 2020
Embargo period ended May 13, 2020
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans May 21, 2020
CDEC Final Recommendation posted May 25, 2020
Redaction requests from sponsor on draft CADTH review report(s) received June 04, 2020
Clarification:

- No redactions requested by the sponsor

Final CADTH review report(s) posted July 03, 2020